Nkarta vs Cartesian Therapeutics
NKTX and RNAC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NKTX and RNAC compare
Cartesian Therapeutics is the larger company, worth 2.3 times as much as Nkarta ($192M against $85.2M).
Nkarta scores higher on the StockData Score (7 against 1 for Cartesian Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NKTX | RNAC |
|---|---|---|
| Size and price | ||
| Market cap | $85.2M | $192M |
| Share price | $1.19 | $6.36 |
| Change, 1 year | −39.3% | −12.9% |
| Change, 5 years | −93.1% | −93.4% |
| Beta (5Y) | 1.18 | 1.39 |
| Employees | 108 | 75 |
| StockData Score | ||
| Total score | 7 (better) | 1 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 188× |
| P/B | 0.4× | – |
| FCF yield | −120% | −46.7% (better) |
| Growth | ||
| Revenue growth, 5Y average | – | −30.0% |
| Profitability | ||
| Operating margin | – | −15541% |
| Net margin | – | −12435% |
| FCF margin | – | −8770% |
| Return on equity | −46.6% | – |
| Return on invested capital | −194% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 5.79 | 8.38 (better) |
| Altman Z-score | −3.83 (better) | −5.12 |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 82.9% | 29.3% |
| Held by insiders | 35.8% | 55.7% |
| Insider net buying, 12 months | −$70.4K | −$52.9K (better) |
| Short interest, % of float | 8.3% | 14.3% |
Go deeper
- NKTX stock overview
- NKTX income statement
- NKTX valuation and score
- RNAC stock overview
- RNAC income statement
- RNAC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.